Cellular compositions and methods of treatment i
AssigneeMesoblast International Sarl
InventorsPeter BRINK, Ira COHEN, Richard LIN, Sergey DORONIN, Irina POTAPOVA, Virginijus VALIUNAS, Dan DEVINE, Anthony SANDRASAGRA, Nick LOIZOS, Silviu ITESCU
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to cellular compositions that are modified to introduce a nucleic acid or vector expressing the same. Such compositions may be used to deliver nucleic acid to a target cell and treat disease such as cancer.
Claims33
A method of delivering an oligonucleotide into a target cell, the method comprising contacting a target cell with a mesenchymal lineage precursor or stem cell expressing one or more of the markers selected from the group consisting of α1, α2, α3, α4 and α5, αv, β1 and β3, wherein said cell has been modified to introduce an oligonucleotide or a vector expressing the oligonucleotide.
A method of treating cancer in a subject, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells expressing one or more of the markers selected from the group consisting of α1, α2, α3, α4 and α5, αv, β1 and β3, wherein said cells are modified to introduce an oligonucleotide or a plasmid expressing the oligonucleotide.
A composition comprising mesenchymal lineage precursor or stem cells expressing one or more of the markers selected from the group consisting of α1, α2, α3, α4 and α5, αv, β1 and β3, wherein said cells are modified to introduce an inhibitory oligonucleotide or comprise a vector expressing the inhibitory oligonucleotide.
(canceled)
(canceled)
-17. (canceled)
(canceled)
-22. (canceled)
(canceled)
(canceled)
-31. (canceled)
-36. (canceled)
(canceled)
-42. (canceled)
Dependencies are inferred from the claim text.